Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia

This article was originally published here

The phase III COVACTA study of tocilizumab did not reach its primary endpoint of improved clinical status in hospitalised adult patients with severe Covid-19 associated pneumonia. Roche’s trial

The post Roche’s tocilizumab fails to achieve primary endpoints for Covid-19-related pneumonia appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply